Jae Moon Lee
Kainos Medicine Inc., South Korea
Scientific Tracks Abstracts: J Neurol Disord
Current standard of care for Parkinson�s disease is symptomatic treatments by supplementing dopamine or dopamine agonists or analogous mechanisms, and the disease modifying treatment is one of the major unmedical needs to block the progression. KM-819 is an orally active small molecule drug developed as an inhibitor for FAF1, a proapoptotic protein, targeting various degenerative diseases. It has shown superior efficacy of neuroprotection in cell models and of dopaminergic neuron protection in midbrain in various animal models of Parkinson�s disease as well as improvement of behavioral tests, suggesting this drug has potential capability of slowing or stopping the progression of the disease. It has also shown inhibition of alpha-synuclein accumulation in cells. We have completed Phase 1 clinical trial for KM-819, randomized, double-blind, placebo-controlled study. The study is divided into part A (single ascending dose) and part B (multiple ascending dose) for evaluation of safety, tolerability, and pharmacokinetics as well as various pharmacodynamics markers for KM-819 in healthy volunteers. The study results showed no drug-related serious AEs and high safety profile in human. Also, the PK study showed dose-proportional exposure with higher in elderly group, ideal for Parkinson�s drug. We are currently planning for phase 2 in patients focusing on investigation of the drug�s efficacy of slowing down or halting the progression of the disease.
Jae Moon Lee completed his PhD from Duke University and Post-doctorate from Duke University School of Medicine. He is the VP of Kainos Medicine, a clinical stage Korean biotech company. He has published more than 15 papers in reputed journals.
E-mail: jlee@kainosmedicine.com
Neurological Disorders received 1253 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 